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Abstract Zinc sulfate (ZS) has been used for the treat-
ment of acute cutaneous leishmaniasis (CL) in both forms
of in vivo and in vitro recently. The aim of the present
study was to compare the efficacy of intralesional injection
of ZS 2 % solution with intralesional glucantime in the
treatment of acute CL. In this double-blind randomized
clinical trial, 80 cases with acute old world dry type CL
were enrolled in the study. The treatment protocol in the
first group consisted of intralesional injection of ZS 2 %
vials once a week for 10 weeks or sooner in case of
complete resolution of the lesions. In the second group,
intralesional glucantime once a week for 10 weeks or
sooner in case of complete resolution of the lesions were
used. In both groups cryotherapy was performed once
every other week for 10 weeks. In ZS versus second group,
partial and complete clinical response was observed with
fewer injections although this difference was not statisti-
cally significant. In addition, we found that the trend of
treatment in second group was faster but again it was not
significant [partial treatment: hazard ratio (HR) 1.4, 95 %
CI 0.7–2.9; complete treatment: HR 1.3, 95 % CI 0.6–2.8].
The results of this study showed that the intralesional
injection of ZS 2 % solution was as effective as glucantime
on the healing of the acute old world dry type CL.
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Introduction
Leishmaniasis is a parasitic disease that is endemic in some
developing countries (Ashford 2000) such as Iran. The most
common pathogens are Leishmania major and Leishmania
tropica. Anthroponotic cutaneous leishmaniasis (ACL)
caused by L. tropica is found mainly in areas of Bam and
Kerman (Sharifi et al. 1998), southeast of Iran. The clinical
features of ACL consist of dry or late ulcerative lesion
(Firooz et al. 2004). The first line-therapy for ACL, accord-
ing to WHO recommendation, is the pentavalent antimony
compounds such as meglumine antimoniate (Glucantime)
(Minodier and Parola 2007). Other treatments for cutaneous
leishmaniasis (CL) are antifungal agents, azithromycin,
paromomycin ointment, and physical treatment like cryo-
therapy (cryosurgery) (Prata et al. 2003; Dogra et al. 1990; Al
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majalio and Routh 1997; Esfandiarpour and Alavi 1997). In
recent researches ZS has been studied to treat the disease,
although there are some controversies regarding the efficacy
of ZS in the treatment of cutaneous leishmanniasis (Firooz
et al. 2004; Iraji et al. 2004).
The idea behind the usage of ZS for CL is that zinc
deficiency can change immune functions prematurely from
predominantly cellular Th1 responses to humeral Th2
responses (Prasad 2009a, b). On the other hand, the
inhibitory effects of ZS on both L. major and L. tropica
amastigotes in vivo and in vitro have been confirmed.
Moreover, promising results have been reported on the
treatment of CL with both oral and intralesional adminis-
trations of ZS (Firooz et al. 2004). The aim of the present
study was to compare the efficacy of intralesional injection
of ZS 2 % solution with intralesional glucantime in the
treatment of ACL which is named as acute old world dry
type CL. According to literature review, this is the first
study on the efficacy of intralesional ZS in Kerman
Province.
Materials and methods
Study area
This study was carried out in some clinics of Kerman
University of Medical Sciences, from October 2008 to
December 2010. Kerman is located in the southeast of Iran,
surrounded by mountains, has a moderate climate and the
average annual rainfall is 135 mm. Kerman is known as an
endemic focus of L. tropica (Sharifi et al. 2012).
Preparation of ZS 2 % solution
ZS solution (2 % w/v) was prepared by dissolving 3.56 g
ZnSO47H2O = (equal to 2 g ZS base) in de-ionized water
Hydrated zinc sulfate (ZnSO47H2O) was purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA).
The ZS solution was sterilized in two steps: Firstly, the
ZS solution was filtered through a 0.22 micron syringe
filter (Millipore, USA), then it was re-sterilized in an
autoclave (Mahzad-Kala, Iran) at 121 C for 20 min in
5 ml borosilicate screw capped vials with Neoprene rubber
caps. The sterility test was carried out according to USP
direct method. The injection process was: The selected
lesions were first cleaned by Betadine, then 1–3 ml of
glucantime or ZS was injected intradermally via an insulin
syringe for the entire lesion until the surface blanched out
(according to WHO suggestion for glucantime injection)
(World Health Organization 1984).
Sampling
One hundred and fifty patients were screened for this
double blinded randomized clinical trial. Eighty CL
patients were signed an informed consent and enrolled
and randomized with random number table. A sample
size of 40 participants per treatment group was planned,
a probability of a type I error at a = 0.05 and b = 0.1
to determine a 20 % difference between intralesional
injection of ZS 2 % solution with intralesional glucan-
time. The inclusion criteria were as fallow; the presence
of parasitological confirmed lesion(s) of CL and the age
of 5–60 years. To confirm the leishmaniasis, direct
smear was taken by scraping of the active border of all
lesions and stained with Giemsa to find leishman bodies.
In the case of negative smear a biopsy was done. No
concomitant treatment was allowed and a washout per-
iod of at least one month was required. Informed con-
sent was taken from all of the patients and for those
below 18 years a parental one was written before
randomization.
Patients with the following criteria were excluded: dis-
ease duration more than 6 months, those with a history of
hypersensitivity to glucantime or ZS, pregnant or nursing
women, those with more than five lesions, those with
lesions with size of 5 cm or more (Firooz et al. 2004), and a
history of any anti-leishmanial therapy during last four
weeks.
Review board in ethics committee of Kerman University
of Medical Sciences approved the study, under number
K-85/30 and the Australian clinical trial registration
(ACTR) number was: ACTRN12609000115235.
For the first group intralesional ZS 2 % solution was
injected once every week until 10 weeks or until complete
healing if happened earlier, plus cryotherapy at -196 C
(liquid nitrogen) was done in the same session, as contact
cryotherapy for 5–10 s to the infected site, once every other
week until 10 weeks or until early complete healing. For
the second group intralesional glucantime (435 mg of
sb5?, active antimony) (Rhone-Poulenc, Paris, France)
15 mg/kg of active ingredient (antimony) once every week
until 10 weeks or until early positive response plus cryo-
therapy the same as the first group.
Clinical assessment
The size of indurations’ lesions was measured in two
perpendicular directions using transparent paper at the
baseline, weekly during treatment, and at the end of the
course by observer blinded to the treatment option.
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The criteria for recovery
The response to the treatment was defined as fallow;
complete response (100 % clinical response plus negative
smear), partial response (more than 75 % reduction of the
size of the lesion in comparison to the baseline), no
response (less than or equal to 75 % reduction of the size of
the lesion in comparison to the baseline or an increase in
the size of the lesion) (Firooz et al. 2004).
Statistical analysis
Having compared demographic and baseline data of sub-
jects in two groups, the data file were converted in long
format in a way which each record showed the data of
every subjects in one session. Then, the area of each lesion
was computed based on its dimensions. In our analysis, no
response to treatment was defined if the area of a lesion
decreased less than 75 %, partial treatment if decreased
between 75 and 99 %, and complete treatment if decreased
100 % compared to its baseline area.
In order to compare the response to treatment of subjects
in two groups, we used Cox regression model. Two types
of models were constructed: (1) the event of interest was
complete treatment, (2) the event of interest was partial or
complete treatment. Since the area of lesions and the
duration of lesion before treatment had significant differ-
ence in two groups, in Cox regression models, crude and
adjusted hazard ratios (HR) were computed to compare the
rate of response to treatment of subjects in two groups.
These analyses were done using Stata version 10.
Results
Of eighty patients participated in the study, 46 patients com-
pleted the study, consisting of 22 patients (10 males and 12
females) in theZS-treated group and 24patients (12males and
12 females) in the glucantime-treated group. Themain reason
of drop out was lost to follow up in all of the patients except in
one which had severe necrosis in the ZS-treated group. In
average, each participant was followed for 4.1 ± 2.6 weeks.
Participants’ mean age was 24.5 ± 14.2 years; most of them
were female (n = 42, 52.5 %). There was no significant dif-
ference between compared groups’ baseline characteristics
(Table 1). The results of this study showed that, most partic-
ipants had one lesion in their body (ZS: n = 32, 80 % vs.
glucantime: n = 29, 72.5 %; P = 0.37), the most frequent
locationof the lesionswas patients’ hand (ZS: n = 35, 67.3 %
vs. glucantime: n = 36, 65.45 %; P = 0.2). The most fre-
quent shape of lesions was plaque in zinc group (n = 17,
32.7 %) versus nodule in glucantime group (n = 19, 34.5 %);
this difference was statistically significant (P = 0.00); simi-
larly there was a significant difference in zinc versus glucan-
time group regarding the mean size, and duration of lesions at
baseline. Other lesion characteristics did not show significant
difference between both groups (Table 1). In zinc versus
glucantime group, partial and complete treatment was
observed with fewer injections, although none of these
differences were statistically significant. Before showing
partial treatment, in average each lesion got 4.5 ± 2.6
injections (ZS: 4.7 ± 2.6 vs. glucantime group: 4.3 ± 2.7;
P = 0.4); moreover, before showing complete treatment, in
average each lesion got 6.8 ± 2.2 injections (ZS: 7.4 ± 1.9
vs. glucantime group 6.2 ± 0.7, P = 0.16). Having used
Cox regression model, we found that the trend of treatment
in second group was rapidly, but it was not statistically
significant (partial treatment: HR 1.4, 95 % CI 0.7–2.9;
complete treatment: HR 1.3, 95 % CI 0.6–2.8). Adjustment
for the initial size of the lesion and its duration did not
change the pattern (Table 2). There were no major side
effects in both groups. Pain was observed in all patients of
both groups. In Zinc group four patients developed necrosis
of the site of the injection while this was not observed in
Table 1 Comparing main characteristics of subjects classified by their received treatments
Variable Glucantime (n = 40) ZS (n = 40) P value
Mean (SD) of age (year) 22.12 ± 1.99 26.84 ± 2.47 0.14
Mean (SD) of duration of lesions (month) 2.66 ± 0.29 3.93 ± 0.31 0.004
Mean (SD) of number of lesions 1.37 ± 0.11 1.3 ± 0.1 0.62
Mean (SD) of the size of lesions in the first visit (mm2) 3.61 ± 0.63 8.33 ± 2.35 0.056
Mean (SD) of follow up (week) 5.73 ± 0.48 5.03 ± 0.45 0.29
Sex
Male 21 (52.5 %) 17 (42.5 %) 0.37
Female 19 (47.5 %) 23 (57.5 %)
Response to treatment
No response 19 (47.5 %) 19 (47.5 %) 0.36
Partial 2 (5 %) 1 (2.5 %)
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glucantime group at all (P = 0.11). Assessing the site of
necrosis in these patients was forearm in two, face in one,
and dorsum of the foot in one of them. The necrosis was
mild in three patients and was alleviated spontaneously
after one week treatment, but it was severe in one of the
patient which resulted in the cessation of the therapy. In this
patient the location of injection was on the dorsum of
the foot and the necrosis was not resolved by medical
treatment, therefore, surgical intervention by full thickness
graft
was done.
Discussion
The results of this study indicated that intralesional injec-
tion of ZS 2 % solution was as effective as glucantime in
the matter of healing of the acute old world dry type CL.
This study showed that no significant differences between
the effects of ZS 2 % solution and glucantime, except the
mean of duration of lesions, that ZS 2 % treatment would
take longer to heal lesions.
Zinc plays a role in determination of the leishmanol-
ysin molecule’s structural features. The leishmanolysin
molecule mediates attachment and internalization of the
parasite through an interaction with macrophage surface
molecules. Also, was showed that zinc was less effective
than in the control subjects in CL patients. The authors
claimed that the mentioned changes could be a part of
defense strategies of organism (Firooz et al. 2004; Prasad
2009a, b).
Najim et al. studied in vitro sensitivities of promastig-
otes and axenic amastigotes of both L. major and L. tropica
to ZS. In their study the lethal dose 50 % (LD50) was
calculated and compared to the pentavalent antimony
compounds. The results showed that the two forms of both
strains were sensitive to ZS and their respective LD50 were
lower compared to the pentavalent antimony compound.
To confirm the results, they administered oral ZS to the
mice with CL and they found the positive effects of oral ZS
in the treatment of CL lesions (Najim 1998).
In another clinical trial, the efficacy of intralesional
administration of ZS solution 2 % was compared with
sodium stibogluconate or 7 % sodium chloride solution in
the treatment of ACL. Thirty-three of a total of the 38
lesions (84.8 %) that were treated by intralesional ZS 2 %
solution were cured after only one injection and 94.7 % of
the lesions were completely healed following administra-
tion of a maximum of two intralesional injections with a
10–15 day interval (Sharquie et al. 1997; Najim et al.
2006). The results of another trial conducted on 130 ACL
patients showed that administration of oral ZS had a dra-
matic effect on the healing of the lesions, in which, 83.9 %
of the lesions in those treated with 2.5 mg/kg/day oral ZS
were cured after a 31.8 ± 1.8 days. The cure rate was 93.1
and 96.9 % in the groups that were treated with oral ZS
5 mg/kg/days for 29.9 ± 1.7 days and 10 mg/kg/days for
28.3 ± 1.4 days, respectively (Sharquie et al. 2001). In
another study, in 2004, Iraji et al. evaluated 66 ACL
patients of which 35 patients received meglumine antim-
onate (MA) and 31 received ZS. The cure rates were 60
and 83.8 % for MA and ZS respectively. After the second
and fourth weeks, the efficacy of treatment with ZS was
higher than that with MA (P = 0.01), but after 6 weeks of
the treatment no significant differences were observed
between the two groups (P = 0.05) (Iraji et al. 2004).
Recent study proposed that one intralesional injection of
ZC 2 % has had lower healing rate versus those received.
Glucantime (33.3 vs. 80 %) (Maleki et al. 2012).
In a recent study in Iran, 72 patients with CL lesions less
than 8 weeks were recruited in a double-blinded random-
ized clinical trial, in an area endemic for L. major (Firooz
et al. 2004). They were treated with six injection of weekly
intralesional glucantime and ZS. Thirteen patients with 19
lesions in the glucantime group and 22 patients with 31
lesions in the ZS group completed the trial. Complete re-
epithelialization was observed in 2 (10.5 %) and 19
(61.3 %) lesions in the ZS and glucantime groups,
respectively, 1 week after the end of treatment (P\ 0.05).
They concluded that a six-week course of weekly intrale-
sional injections of ZS 2 % solution was less effective than
glucantime in the treatment of acute old world CL (Firooz
et al. 2004).
In our study accomplished in an endemic area for
L .tropica the efficacy of ZS was better in comparison with
Firooz et al. (2004) study in an area endemic for L. major.
Table 2 Comparing of the response to treatments
Hazard ratio (95 % confidence interval)
Crude Adjusted for the
Lesion size in the first visit Duration of lesion Size and the duration of lesion
Complete treatment 1.37 (0.66–2.86) 1.26 (0.57–2.77) 1.39 (0.66–2.95) 1.28 (0.57–2.86)
Partial or complete treatment 1.32 (0.63–2.76) 1.21 (0.55–2.67) 1.39 (0.64–3.01) 1.27 (0.56–2.91)
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The discrepancy could be due to the causative Leishmania
species (L. tropica vs. L. major). Different susceptibility of
the parasites to zinc derivatives in different geographical
regions should also be a probable factor.
The side effects of ZS 2 % treatment was the necrosis at
the site of injection in four cases that this effect was also
seen in the study of Iraji et al. (2004). We suggest that not
to be injected ZS in places with thin skin such as dorsum of
the foot. The main limitation of the current study was that
we did not follow up the patients after the end of the
treatment. We also did not assess the degree of pain at the
site of injection in these two groups.
Conclusion
In the current study interalesional injection of ZS 2 %
solution has the same efficacy as glucantime. So, it seems
that in case of hypersensitivity and/or resistance to penta-
valent antimony compounds we may use intralesional
administration of ZS, it could worthy to mention that
although pentavalent antimony compounds are expensive
and their administration could be associated with several
side effects, they are still the first-line drugs in the antile-
ishmanial armamentarium.
Acknowledgments The authors would like to acknowledge the
reviewers of our drafts and Afzalipour hospital of University of
Medical Sciences, Kerman, Iran.
Conflict of interest The authors confirmed that they have no
financial or personal relationships which may have inappropriately
influenced them in writing this paper.
References
Al majalio O, Routh HB (1997) A two year study of liquid nitrogen
therapy in cutaneous leishmaniasis. Int J Dermatol 36(6):36–460
Ashford RW (2000) The leishmaniasis as emerging and reemerging
zoonoses. Int J Parasitol 30:1269–1281
Dogra J, Aneja N, Lal BB, Mishra SN (1990) Cutaneous leishman-
iasis in India: clinical experience with itraconazole. Int J
Dermatol 29:661–662
Esfandiarpour I, Alavi F (1997) Evaluating the efficacy of allopurinol
and meglumine antimoniate (Glucantime) in the treatment of
cutaneous leishmaniasis: a pilot study. Int J Dermatol
36(1):59–60
Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F,
Nilforoushzadeh M, Pazoki-Toroudi H, Dowlati Y (2004)
Intralesional injection of 2 % zinc sulfate solution in the
treatment of acute old world cutaneous leishmaniasis: a
randomized, double-blinded, controlled clinical trial. J Drug
Dermatol 4:73–77
Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ (2004)
Comparison of intralesionally injected zinc sulfate with meglu-
mine antimoniate in the treatment of acute cutaneous leishman-
iasis. Dermatology 209(1):46–49
Maleki M, Karimi Gh, Tafaghodi M, Raftari S, Nahidi Y (2012)
Comparison of intralesional two percent zinc sulfate and
glucantime injection in treatment of acute cutaneous leishman-
iasis. Indian J Dermatol 57(2):118–122
Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment.
Travel Med Infect Dis J 5:150–158
Najim RA (1998) Zinc sulfate in the treatment of cutaneous
leishmaniasis: an in vitro and animal study. Inst Oswaldo Cruz
93:831–833
Najim RA, Sharquie KE, Al-Zubaidy SA (2006) Possible mechanisms
of action of the compounds injected intralesionally in the
treatment of cutaneous leishmaniasis, in addition to their direct
effects on the parasites. Ann Trop Med Parasitol 100(1):33–38
Prasad AS (2009a) Zinc: role in immunity, oxidative stress and
chronic inflammation. Curr Opin Clin Nutr Metab Care
12:646–652
Prasad AS (2009b) Impact of the discovery of human zinc deficiency
on health. J Am Coll Nutr 28:257–265
Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva
JC, de Paula EV, Pimenta Junior FG, Giraldo LE (2003) Efficacy
of azithromycin in the treatment of cutaneous leishmaniasis. Rev
Soc Bras Med Trop 36(1):65–69
Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour
A (1998) Cutaneous leishmaniasis in primary school children in
the south-eastern Iranian city of Bam, 1994–1995. Bull World
Health Organ 76(3):289–293
Sharifi F, Sharifi I, Zarean M, Hakimi Parizi M, Aflatoonian M,
Harandi MF, Zahmatkesh R, Mashayekhi M, Kermanizadeh A
(2012) Spatial distribution and molecular identification of
Leishmania species from endemic foci of south-eastern Iran.
Iran J Parasitol 7(1):45–52
Sharquie KL, Najim RA, Farouj IB (1997) Comparative controlled
trial of intralesionally administered zinc sulfate, hypertonic
sodium chloride and pentavalent antimony compound against
acute cutaneous leishmaniasis. Clin Exp Dermatol 22:169–173
Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ (2001) Oral zinc
sulfate in the treatment of acute cutaneous leishmaniasis. Clin
Exp Dermatol 26:21–26
World Health Organization (1984) The leishmaniasis. Report of a
WHO expert committee. WHO Tech Rep Ser 701
J Parasit Dis (July-Sept 2016) 40(3):935–939 939
123
